Order Article Reprints

Rittberg R, Harlos C, Rothenmund H, Das A, Tabori U, Sinha N, Singh H, Chodirker B, Kim CA. Immune Checkpoint Inhibition as Primary Adjuvant Therapy for an IDH1-Mutant Anaplastic Astrocytoma in a Patient with CMMRD: A Case Report—Usage of Immune Checkpoint Inhibition in CMMRD. Current Oncology. 2021; 28(1):757-766. https://doi.org/10.3390/curroncol28010074

Rittberg, Rebekah, Craig Harlos, Heidi Rothenmund, Anirban Das, Uri Tabori, Namita Sinha, Harminder Singh, Bernie Chodirker, and Christina A. Kim. 2021. "Immune Checkpoint Inhibition as Primary Adjuvant Therapy for an IDH1-Mutant Anaplastic Astrocytoma in a Patient with CMMRD: A Case Report—Usage of Immune Checkpoint Inhibition in CMMRD" Current Oncology 28, no. 1: 757-766. https://doi.org/10.3390/curroncol28010074

Rittberg, R., Harlos, C., Rothenmund, H., Das, A., Tabori, U., Sinha, N., Singh, H., Chodirker, B., & Kim, C. A. (2021). Immune Checkpoint Inhibition as Primary Adjuvant Therapy for an IDH1-Mutant Anaplastic Astrocytoma in a Patient with CMMRD: A Case Report—Usage of Immune Checkpoint Inhibition in CMMRD. Current Oncology, 28(1), 757-766. https://doi.org/10.3390/curroncol28010074